WESTMINSTER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that updated results from
a Phase 1/2 study evaluating the Company's novel antifolate PDX
(pralatrexate) in patients with relapsed or refractory non-Hodgkin's
lymphoma and Hodgkin's disease have been accepted for presentation at the
American Society of Hematology's 48th Annual Meeting, to be held December 9
- 12 in Orlando.
Owen O'Connor, M.D., Ph.D., Head of the Laboratory of Experimental
Therapeutics for Lymphoproliferative Malignancies, Lymphoma and Development
Chemotherapy Services, Memorial Sloan-Kettering Cancer Center (MSKCC), is
scheduled to report updated results from the on-going study in an oral
presentation titled "Pralatrexate (PDX) Produces Durable Complete
Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral
T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience" on Monday,
December 11 at 11:45 AM ET.
A copy of the abstract (#556063) is currently available on the American
Society of Hematology's web site, http://www.hematology.org.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the "Risk
Factors" section of the Company's Form 10-K for the year ended December 31,
2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The
Company does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentation as a result of new
information, future events or otherwise. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
http://www.hematology.org
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227,
jneiman@allos.com
|
